Document is current
Any future updates will be listed below
-
Authors
Hennes, Elisabeth
Lucas, Belén https://orcid.org/0009-0008-1426-5815
Scholes, Natalie S. https://orcid.org/0000-0002-1053-4079
Cheng, Xiu-Fen
Scott, Daniel C.
Bischoff, Matthias https://orcid.org/0009-0002-4046-7580
Reich, Katharina
Gasper, Raphael https://orcid.org/0000-0002-7780-0773
Lucas, María https://orcid.org/0000-0002-7854-4249
Xu, Teng Teng https://orcid.org/0000-0001-9129-913X
Rossini, Sofia https://orcid.org/0000-0001-6429-9425
Pulvermacher, Lisa-Marie
Dötsch, Lara
Imrichova, Hana https://orcid.org/0000-0003-0385-1823
Brause, Alexandra
Führer, Siska https://orcid.org/0009-0000-4334-221X
Naredla, Kesava Reddy
Sievers, Sonja https://orcid.org/0000-0003-0854-4507
Kumar, Kamal
Janning, Petra
Orabona, Ciriana https://orcid.org/0000-0003-3113-0572
Gersch, Malte https://orcid.org/0000-0003-2767-9589
Murray, Peter J. https://orcid.org/0000-0001-6329-9802
Schulman, Brenda A. https://orcid.org/0000-0002-3083-1126
Winter, Georg E. https://orcid.org/0000-0001-6606-1437
Ziegler, Slava https://orcid.org/0000-0003-4398-7741
Waldmann, Herbert https://orcid.org/0000-0002-9606-7247
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 3 November 2025
First Online: 7 January 2026
Competing interests
: G.E.W. is scientific founder and shareholder of Proxygen and Solgate Therapeutics and shareholder of Cellgate Therapeutics. G.E.W. is on the Scientific Advisory Board of Proxygen and Nexo Therapeutics. The Winter laboratory has received research funding from Pfizer. D.C.S. and B.A.S. are co-inventors of intellectual property related to DCUND1 inhibitors licensed to Cinsano. B.A.S. is a member of the scientific advisory boards of Proxygen and Lyterian. The other authors declare no competing interests.
